CN103432088B - Albendazole large tablets and preparation technology thereof - Google Patents

Albendazole large tablets and preparation technology thereof Download PDF

Info

Publication number
CN103432088B
CN103432088B CN201310373608.4A CN201310373608A CN103432088B CN 103432088 B CN103432088 B CN 103432088B CN 201310373608 A CN201310373608 A CN 201310373608A CN 103432088 B CN103432088 B CN 103432088B
Authority
CN
China
Prior art keywords
albendazole
parts
bolus
add
large tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310373608.4A
Other languages
Chinese (zh)
Other versions
CN103432088A (en
Inventor
房春林
杨海涵
李犹平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Qiankun Veterinary Pharmaceutical Co Ltd
Original Assignee
Chengdu Qiankun Veterinary Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Qiankun Veterinary Pharmaceutical Co Ltd filed Critical Chengdu Qiankun Veterinary Pharmaceutical Co Ltd
Priority to CN201310373608.4A priority Critical patent/CN103432088B/en
Publication of CN103432088A publication Critical patent/CN103432088A/en
Application granted granted Critical
Publication of CN103432088B publication Critical patent/CN103432088B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses albendazole large tablets and a preparation technology thereof. The large albendazole tablets comprise 25wt% of glucosyl beta-cyclodextrin and 41.6wt% of albendazole as well as various auxiliary materials such as starch, apple green, brilliant blue, talcum powder, magnesium stearate and aluminium hydroxide. The preparation technology comprises the following steps of: preparation of starch slurry and a glucosyl beta-cyclodextrin inclusion compound of the albendazole, mixing, pelleting and tabletting. The albendazole large tablets have the advantages that the glucosyl beta-cyclodextrin inclusion compound is used for inclusion of the albendazole so as to improve the slow-release effect and the bioavailability of the albendazole, so that the effective haemoconcentration plasma concentration time of medicines is prolonged, the problem of difficulty in absorption by gastrointestinal tracts is solved, and the pharmaceutical effect is improved; the forming effect of the large tablets is good by the reasonable distribution of the contents of the components in the albendazole large tablets in combination with an inclusion process. The preparation technology is simple and convenient to operate. The albendazole large tablets are used for treating nematodosis in cattle gastrointestinal tracts in clinic, the expelling rate reaches 100%, after the albendazole large tablets are taken for 7 days, the negative conversion ratio and decrement rate of eggs are respectively 86.7% and 98.9%, after 14 days, the negative conversion ratio and the decrement rate reach 100% respectively, and the parasite expelling effect of the albendazole large tablets is obviously superior to those of medicine control groups.

Description

Albendazole bolus and preparation technology thereof
Technical field
The present invention relates to the technical field of albendazole preparation for animals, particularly relate to a kind of albendazole bolus and preparation technology thereof.
Background technology
Albendazole system benzimidazoles derivative, be white or off-white powder, odorless, tasteless, water insoluble, be slightly soluble in acetone or chloroform, its in vivo rapid metabolization be sulfoxide, sulfone alcohol and 2-amine sulfone alcohol.The polymerization of parasite intestinal wall cell cytosol microtubule system is suppressed to intestinal nematodes selectivity and irreversibility, block it to absorb the picked-up of multiple nutrients and glucose, polypide endogenous glycogen is caused to be exhausted, and suppress fumaric reductase system, stop the generation of adenosine triphosphate, cause polypide to survive and to breed.
Veterinary is in Clinical practice, and albendazole is benzimidazole anthelmintic drug the most widely, not only has efficiently multiple nematicide, and also has stronger dispel effect to some trematodiasis and cestode.The albendazole tablet of current research report is mainly conventional tablet, use rear gastrointestinal absorption poor, bioavailability is low, effective haemoconcentration is held time shorter, thus make the drug effect of Albenza not good, hold time to extend effective haemoconcentration, the mode that those skilled in the art generally adopt albendazole is prepared into Emulsion or suspension formulations carries out injection administration.In the Albenza that simultaneously now studies have reported that, albendazole content is lower, mostly be the little weight tablet of 0.025g-0.5g/ sheet, the Albenza of this small dimension is very inconvenient on the livestock animals that the body weight such as cattle are larger, dispensing quantity is more, therefore need to research and develop a kind of dispensing quantity few, veterinary clinic is conveniently applied to the high-load albendazole anthelmintic abnormity bolus of the large domestic animals such as cattle.Owing to changing the content specification of Albenza, compared with little content specification tablet, there is fabricating technology difficulty relatively large, the easy part when tabletting sticking, the problems such as molding effect is bad, and part mass index is as defective in disintegration time, and gastrointestinal absorption is difficult.
Summary of the invention
In view of this, the invention provides a kind of albendazole bolus and preparation technology thereof, the bioavailability of albendazole can be improved, solve that large stretch of albendazole molding effect is bad, part mass index is as defective in disintegration time, gastrointestinal tract is difficult to the problems such as absorption.
For solving above technical problem, technical scheme of the present invention is, provide a kind of albendazole bolus, described albendazole comprises glucityl beta-schardinger dextrin-.
Described glucityl beta-schardinger dextrin-by can improve after inclusion technique technique enclose albendazole medicine slow release effect, increase blood density of medicine hold time and improve bioavailability; Strengthen the stability of medicine; Reduce the toxic and side effects of medicine; For taste masking, protection against the tide with make liquid medicine solidification.Glucityl beta-schardinger dextrin-, compared with other enclose material, has water-soluble good, inclusion rate advantages of higher, is more suitable for the enclose of water-insoluble drug especially albendazole.
Preferably, the constituent of described albendazole bolus, according to mass ratio range, comprising:
Moisture controls within 5%.
Preferably, the specification of described albendazole bolus is 39 × 17 × 9.5mm (long × wide × high).
A preparation technology for albendazole bolus, comprises the steps:
A, take starch 10 parts by weight, and take light green 1.13 parts respectively, light blue 0.37 part, add a small amount of water after three's mixing and stir, then add 25 parts of waters for injection, to stir with steam punching in gel, obtain starch slurry for subsequent use;
B, get glucityl beta-schardinger dextrin-25 parts, join in 30 parts of waters for injection, be heated to 60-80 DEG C, after stirring and dissolving, then add albendazole 41.6 parts, under 60-65 DEG C of condition, stir 1.5-2 hour, drying under reduced pressure, to Han Shui Liang≤5%, obtains the glucityl Benexate Hydrochloride of albendazole;
C, dry gained clathrate is positioned in mixer, add Pulvis Talci 10 parts again, after being uniformly mixed 15 minutes, adding starch 6.4 parts, remix 15 minutes, add the starch slurry made in steps A again, be uniformly mixed and be prepared into soft material, granulate, dry grain, add magnesium stearate 0.2 part, aluminium hydroxide 0.3 part mixing granulate, compression molding.
Compared with prior art, tool of the present invention has the following advantages:
Adopt glucityl beta-cyclodextrin inclusion compound albendazole, improve slow release effect and the bioavailability of albendazole, thus the effective blood concentration time course of prolong drug, solve the problem that gastrointestinal tract is difficult to absorb, increase drug effect.The content of the various component of reasonable distribution albendazole bolus, and in conjunction with clathrate process, make the good forming effect of bolus, quality index is qualified, preparation technology is simple, easy to operate.
Detailed description of the invention
In order to make those skilled in the art understand technical scheme of the present invention better, below in conjunction with specific embodiment, the present invention is described in further detail.
Below in conjunction with embodiment, the specific embodiment of the present invention is further described.Following examples only for technical scheme of the present invention is clearly described, and can not limit the scope of the invention with this.
A preparation technology for albendazole bolus, comprises the steps:
A, take starch 10Kg by weight, and take light green 1.13Kg respectively, light blue 0.37Kg, add a small amount of water after three's mixing and stir, then add 25Kg water for injection, to stir with steam punching in gel, obtain starch slurry for subsequent use;
B, get glucityl beta-schardinger dextrin-25Kg, join in 30Kg water for injection, be heated to 60-80 DEG C, after stirring and dissolving, then add albendazole 41.6Kg, under 60-65 DEG C of condition, stir 1.5-2 hour, drying under reduced pressure, to Han Shui Liang≤5%, obtains the glucityl Benexate Hydrochloride of albendazole;
C, dry gained clathrate is positioned in mixer, add Pulvis Talci 10Kg again, after being uniformly mixed 15 minutes, add starch 6.4Kg, remix 15 minutes, add the starch slurry made in steps A again, be uniformly mixed and be prepared into soft material, granulate, dry grain, add magnesium stearate 0.2Kg, aluminium hydroxide 0.3Kg mixing granulate, namely compression molding obtains the albendazole bolus of good forming effect.
The specification of every a slice albendazole bolus is: 39 × 17 × 9.5mm, punch die: long 39mm × wide 17mm, and without word drift, equipment is rushed in 11 punchings, 21.Obtain the special-shaped bolus that tablet is 6g weight, packaging.Detect according to the regulation of " People's Republic of China's veterinary drug allusion quotation ", obtain the quality index such as the disintegration time of whole albendazole bolus qualified, disintegration time reaches less than 3 minutes.
So the constituent of the albendazole bolus obtained and content thereof, count by weight: glucityl beta-schardinger dextrin-25%, starch 16.4%, albendazole 41.6%, light green 1.13%, light blue 0.37%, Pulvis Talci 10%, magnesium stearate 0.2%, aluminium hydroxide 0.3, moisture control within 5%.
Below gained albendazole bolus clinical practice test of the present invention is described:
1 materials and methods
1.1 trial drug
Albendazole Special-shaped sheet, i.e. albendazole bolus of the present invention, specification 6g, 2500mg tabletting sticking, Chengdu Qiankun Animal Drug Industry Co., Ltd. produces.Lot number, 20130102.
1.2 control drug
Albendazole tablet, specification 250mg, Sichuan Qian Xing animal pharmaceutical estate company limited produces, through the product that is up to the standards.
1.3 experimental animals and medication
Choose certain cattle farm and infect the serious cattle 90 of nematicide, be divided into drug test group, drug control group, blank group etc. 3 groups, often organize 30, three groups of test cattle are fed management under similarity condition.
Drug test group: oral albendazole Special-shaped sheet, dosage is 15mg/kg body weight.
Drug control group: oral albendazole sheet, dosage is 15mg/kg body weight.
Blank group: not administration of falling ill.
1.4 test method
The previous day is just carried out egg count to the test cattle manure that primary election infects nematicide serious in test, check worm's ovum number (PEG) contained by every g feces, and by above-mentioned medication administration, each group of 7 days upon administration, 14 days acquisition test cattle manure just carries out egg count, checks worm's ovum number (PEG) contained by every g feces.
1.5 efficacy determination
Negative rate on the egg=(worm's ovum turn out cloudy number of animals/experimental animal number) × 100%.
Redution of eggs=[before (before anthelmintic after PEG-anthelmintic PEG)/anthelmintic PEG] × 100%.
2 result of the tests
Result of the test shows, the expeling rate of albendazole Special-shaped sheet to cattle gastrointestinal nematode parasites reaches 100%, medication after 7 days Negative rate on the egg and Redution of eggs be respectively 86.7% and 98.9%, reach 100% after 14 days, anthelminthic effect is obviously better than drug control group.The results are shown in Table 1, table 2.
Table 1 Redution of eggs (%)
Table 2 Negative rate on the egg (%)

Claims (3)

1. an albendazole bolus, is characterized in that, described albendazole bolus is made up of the component of following percentage by weight:
2. albendazole bolus as claimed in claim 1, it is characterized in that, the specification of described albendazole bolus is 39 × 17 × 9.5mm.
3. the preparation technology of the albendazole bolus as described in any one of claim 1 to 2, is characterized in that, comprise the steps:
A, take starch 10 parts by weight, and take light green 1.13 parts respectively, light blue 0.37 part, add a small amount of water after three's mixing and stir, then add 25 parts of waters for injection, to stir with steam punching in gel, obtain starch slurry for subsequent use;
B, get glucityl beta-schardinger dextrin-25 parts, join in 30 parts of waters for injection, be heated to 60-80 DEG C, after stirring and dissolving, then add albendazole 41.6 parts, under 60-65 DEG C of condition, stir 1.5-2 hour, drying under reduced pressure, to Han Shui Liang≤5%, obtains the glucityl Benexate Hydrochloride of albendazole;
C, dry gained clathrate is positioned in mixer, add Pulvis Talci 10 parts again, after being uniformly mixed 15 minutes, adding starch 6.4 parts, remix 15 minutes, add the starch slurry made in steps A again, be uniformly mixed and be prepared into soft material, granulate, dry grain, add magnesium stearate 0.2 part, aluminium hydroxide 0.3 part mixing granulate, compression molding.
CN201310373608.4A 2013-08-23 2013-08-23 Albendazole large tablets and preparation technology thereof Expired - Fee Related CN103432088B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310373608.4A CN103432088B (en) 2013-08-23 2013-08-23 Albendazole large tablets and preparation technology thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310373608.4A CN103432088B (en) 2013-08-23 2013-08-23 Albendazole large tablets and preparation technology thereof

Publications (2)

Publication Number Publication Date
CN103432088A CN103432088A (en) 2013-12-11
CN103432088B true CN103432088B (en) 2015-07-01

Family

ID=49685875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310373608.4A Expired - Fee Related CN103432088B (en) 2013-08-23 2013-08-23 Albendazole large tablets and preparation technology thereof

Country Status (1)

Country Link
CN (1) CN103432088B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919745B (en) * 2014-05-08 2017-01-11 成都乾坤动物药业有限公司 Coloring formula and technology of veterinary use benzimidazole vermifuge

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Correlation and in vitro studies on radioactive and nonradioactive albendazole-β-cyclodextrin complex tablets;E.O.Cetin et al;《Pharmazie》;20111231;第66卷;表1 *

Also Published As

Publication number Publication date
CN103432088A (en) 2013-12-11

Similar Documents

Publication Publication Date Title
CN103099793A (en) Tablet and preparation method
CN102935084A (en) Compound ivermectin sustained release tablet and preparation method thereof
CN103142494B (en) Ornidazole oral preparation and preparation method thereof
CN105287607B (en) Animal compound Doxycycline Hyclate florfenicol slowly-releasing microballoon suspension injection
CN103751201A (en) Anti-parasitic orally disintegrating tablet for dogs and cats and preparation method thereof
CN103432088B (en) Albendazole large tablets and preparation technology thereof
CN103705536A (en) Pharmaceutical formula of polyhexamethylene guanidine hydrochloride (PHMG) and preparation method
CN103610658A (en) Immunomodulator slow-release preparation and preparation method thereof
CN105030665B (en) A kind of long-acting veterinary lincomycin hydrochloride injection and preparation method thereof
CN104721207A (en) Drug composition
CN112535664A (en) Water-soluble tilmicosin premix and preparation method thereof
CN107569504B (en) Ambroxol hydrochloride dispersible tablet and preparation method thereof
CN104173310A (en) Stable amoxicillin tablet composition, as well as preparation method and application thereof
CN106924198A (en) Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof
CN102846577B (en) Enteric tablet containing erythromycin cydocarbonate
CN102988429B (en) Pine pollen tablet for preventing alcoholic liver damages
CN104906039A (en) Suspension for injecting tilmicosin and preparation method thereof
CN105030707A (en) Method for preparing clotrimazole buccal tablets on basis of all-powder direct pressing of modified glucose
CN105534980B (en) The pharmaceutical composition and its preparation process of Repaglinide Metformin hydrochloride
RU2599020C1 (en) Tableted drug based on the extract of alchemilla vulgaris
CN108524523A (en) The application of the composition of Meloxicam and Thymol, animal antipyretic-antalgic anti-inflammatory agent and preparation method thereof
CN103315986B (en) A soluble and stable ponazuril composition and a preparation method thereof
CN104208021A (en) Avermectin suspension and preparation method thereof
CN101693019A (en) Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof
CN106563038B (en) Taurine and fat-soluble tea polyphenol compound composition, preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150701

Termination date: 20150823

EXPY Termination of patent right or utility model